KR20240062225A - Composition for improving cognitive function containing enzyme-treated Tenebrio molitor - Google Patents
Composition for improving cognitive function containing enzyme-treated Tenebrio molitor Download PDFInfo
- Publication number
- KR20240062225A KR20240062225A KR1020220141351A KR20220141351A KR20240062225A KR 20240062225 A KR20240062225 A KR 20240062225A KR 1020220141351 A KR1020220141351 A KR 1020220141351A KR 20220141351 A KR20220141351 A KR 20220141351A KR 20240062225 A KR20240062225 A KR 20240062225A
- Authority
- KR
- South Korea
- Prior art keywords
- enzyme
- brown mealworm
- composition
- cognitive function
- mealworm larvae
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 95
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 230000003920 cognitive function Effects 0.000 title claims abstract description 29
- 241000254109 Tenebrio molitor Species 0.000 title description 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 229940088598 enzyme Drugs 0.000 claims description 93
- 208000024827 Alzheimer disease Diseases 0.000 claims description 26
- 235000013305 food Nutrition 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 22
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 19
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 235000013376 functional food Nutrition 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 102000035195 Peptidases Human genes 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- 238000010025 steaming Methods 0.000 claims description 7
- 238000005238 degreasing Methods 0.000 claims description 6
- 108090000637 alpha-Amylases Proteins 0.000 claims description 5
- 102000004139 alpha-Amylases Human genes 0.000 claims description 5
- 229940024171 alpha-amylase Drugs 0.000 claims description 5
- 230000003013 cytotoxicity Effects 0.000 claims description 5
- 231100000135 cytotoxicity Toxicity 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 230000001537 neural effect Effects 0.000 claims description 5
- 108010065511 Amylases Proteins 0.000 claims description 4
- 102000013142 Amylases Human genes 0.000 claims description 4
- 102000005158 Subtilisins Human genes 0.000 claims description 4
- 108010056079 Subtilisins Proteins 0.000 claims description 4
- 108010004032 Bromelains Proteins 0.000 claims description 3
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 3
- 102100022624 Glucoamylase Human genes 0.000 claims description 3
- 108090000526 Papain Proteins 0.000 claims description 3
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 claims description 3
- -1 Protamax Proteins 0.000 claims description 3
- 102400000472 Sucrase Human genes 0.000 claims description 3
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 claims description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 3
- 102000016679 alpha-Glucosidases Human genes 0.000 claims description 3
- 108010019077 beta-Amylase Proteins 0.000 claims description 3
- 235000019835 bromelain Nutrition 0.000 claims description 3
- 229940111205 diastase Drugs 0.000 claims description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 3
- 235000011073 invertase Nutrition 0.000 claims description 3
- 108010009355 microbial metalloproteinases Proteins 0.000 claims description 3
- 230000016273 neuron death Effects 0.000 claims description 3
- 231100001083 no cytotoxicity Toxicity 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 7
- 230000007541 cellular toxicity Effects 0.000 abstract description 4
- 231100000065 noncytotoxic Toxicity 0.000 abstract description 3
- 230000002020 noncytotoxic effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 20
- 238000001035 drying Methods 0.000 description 17
- 239000000843 powder Substances 0.000 description 11
- 239000002994 raw material Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000010609 cell counting kit-8 assay Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 208000010877 cognitive disease Diseases 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000003925 brain function Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000008449 language Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000254173 Coleoptera Species 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000254107 Tenebrionidae Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000007602 hot air drying Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000000861 blow drying Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000011059 hazard and critical control points analysis Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000001682 neurofibril Anatomy 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008010 parenteral excipient Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 갈색거저리 유충 효소처리물을 유효성분으로 포함하는 인지기능 개선용 조성물에 관한 것으로, 이 조성물은 세포 독성이 없고, 신경세포 독성으로부터 신경세포를 보호하는 효과가 있다.The present invention relates to a composition for improving cognitive function containing enzyme-treated brown mealworm larvae as an active ingredient. This composition is non-cytotoxic and has the effect of protecting nerve cells from nerve cell toxicity.
Description
본 발명은 갈색거저리 유충 효소처리물을 포함하는 인지기능 개선용 조성물에 관한 것으로, 보다 상세하게는 갈색거저리 유충을 효소로 처리한 갈색거저리 유충 효소처리물을 포함하는 인지기능 개선용 약학적 조성물, 인지기능 개선용 식품 조성물, 또는 인지기능 개선용 건강기능식품 조성물에 관한 것이다.The present invention relates to a composition for improving cognitive function containing an enzyme-treated product of brown mealworm larvae. More specifically, a pharmaceutical composition for improving cognitive function comprising an enzyme-treated brown mealworm larva obtained by treating brown mealworm larvae with an enzyme, It relates to a food composition for improving cognitive function, or a health functional food composition for improving cognitive function.
의학 기술의 발달과 생활 수준의 향상에 따라, 인간의 평균 수명은 지난 반세기 동안 두 배 가까이 연장되었으며, 전체 인구에 대한 노인 인구의 비율이 급속히 증가하고 있다. 노인 인구의 증가에 따라, 인지기능 장애인 치매 환자가 급증하고, 치매의 치료에 많은 시간과 경제적 부담이 소요될 것으로 예상되므로, 노인성 치매는 21세기 인류가 해결해야 할 최대의 보건 문제로 등장하고 있다. 따라서, 치매를 비롯한 인지기능 장애를 효율적으로 예방 및 치료하기 위한 다양한 연구가 수행되고 있다. 치매는 뇌기능이 손상되어, 기억력, 언어 능력, 판단력, 사고력 등의 지적기능이 지속적이고 전반적인 장애 상태에 있는 것으로서, 특히, 알츠하이머성 질환인 알츠하이머성 치매는 대표적인 노인성 퇴행질환으로서, 암, 심장병에 이어 사망률이 높은 6대 질환 중의 하나이다.With advances in medical technology and improvements in living standards, the average human lifespan has nearly doubled over the past half century, and the ratio of the elderly to the total population is rapidly increasing. As the elderly population increases, the number of dementia patients with cognitive impairment is rapidly increasing, and treatment of dementia is expected to take a lot of time and financial burden. Therefore, senile dementia is emerging as the biggest health problem that humanity must solve in the 21st century. Therefore, various studies are being conducted to efficiently prevent and treat cognitive dysfunction, including dementia. Dementia is a state in which brain function is damaged and intellectual functions such as memory, language ability, judgment, and thinking are continuously and overall impaired. In particular, Alzheimer's disease, Alzheimer's disease, is a representative age-related degenerative disease and is associated with cancer and heart disease. It is one of the six major diseases with high mortality rates.
알츠하이머성 질환은 뇌의 특정 부위에 아밀로이드 베타 (또는 베타 아밀로이드)가 침착된 아밀로이드 플라크(amyloid plaque) 또는 신경원섬유 덩굴(neurofibril tangle)이 축적되어, 신경계 손상 및 뇌의 광범위한 구조 이상을 특징으로 하며, 대부분의 환자에게서 기억상실, 실어증(aphasia), 실행증(apraxia), 실인증(agnosia) 등의 인지증상과 성격변화, 우울, 환각, 착란 등의 신경정신 증상이 나타나는 것으로 알려져 있다Alzheimer's disease is characterized by damage to the nervous system and extensive structural abnormalities in the brain due to the accumulation of amyloid plaques or neurofibril tangles, which are deposits of amyloid beta (or beta-amyloid) in specific areas of the brain. It is known that most patients exhibit cognitive symptoms such as memory loss, aphasia, apraxia, and agnosia, as well as neuropsychiatric symptoms such as personality changes, depression, hallucinations, and confusion.
알츠하이머성 질환은 그 진행과정에서 인지기능 저하뿐만 아니라 성격변화, 초조행동, 우울증, 망상, 환각, 공격성 증가, 수면 장애 등의 정신행동 증상이 흔히 동반되며 말기에 이르면 경직, 보행 이상 등의 신경학적 장애 또는 대소변 실금, 감염, 욕창 등 신체적인 합병증까지 나타나게 된다.As Alzheimer's disease progresses, it is often accompanied by not only cognitive decline but also mental and behavioral symptoms such as personality changes, agitated behavior, depression, delusions, hallucinations, increased aggression, and sleep disorders. In the later stages, neurological symptoms such as stiffness and gait abnormalities occur. Physical complications such as disability, incontinence of urine and feces, infection, and bedsores can occur.
알츠하이머성 질환의 정확한 발병 기전과 원인은 밝혀진 건 없지만, 알츠하이머병 환자의 뇌에선 아밀로이드 베타(Aβ, Abeta 또는 β-amyloid) 단백질이 비정상으로 뒤엉킨 플라크(신경반)가 많이 발견되어, 아밀로이드 베타가 과도하게 생성되어 뇌에 침착하고 뇌 신경세포를 파괴하거나 사멸시켜 뇌 기능을 떨어뜨리는 것으로 알려져 있다.Although the exact pathogenesis and cause of Alzheimer's disease are not known, many plaques (neural plaques) in which amyloid beta (Aβ, Abeta or β-amyloid) protein is abnormally tangled are found in the brains of patients with Alzheimer's disease, resulting in excessive amyloid beta. It is known to be produced rapidly, deposited in the brain, and deteriorating brain function by destroying or killing brain nerve cells.
한편, 예로부터 곤충은 한약재로 자주 이용되어 왔으며 주로 굼벵이, 누에, 매미허물, 동충하초 또는 지네 등 약 30여종이 유용한 곤충자원으로 이용되고 있으며, 현재에는 흰점박이 꽃무지, 밀웜 등 7종이 식품원료로 사용될 수 있도록 식품공전에 등재되어 있다. 곤충은 단백질 함량이 육류에 비해 평균 2배 이상 높으며 무기질, 필수 및 비필수 아미노산, 비타민 등이 풍부하며 지방이 대부분 불포화 지방으로 이루어져 있다. 곤충이 함유하고 있는 영양성분이 인체에 쉽게 흡수될 수 있어 축산물에서 얻어지는 단백질 대체식품으로 대두되고 있다.Meanwhile, insects have been frequently used as herbal medicine since ancient times, and about 30 species, including slugs, silkworms, cicada skin, Cordyceps sinensis, and centipedes, are currently used as useful insect resources, and currently, seven species, including white-spotted radish and mealworms, are used as food ingredients. It is registered in the Food Code for use. The protein content of insects is on average more than twice that of meat, and they are rich in minerals, essential and non-essential amino acids, vitamins, etc., and their fat consists mostly of unsaturated fat. Since the nutrients contained in insects can be easily absorbed by the human body, they are emerging as an alternative to protein obtained from livestock products.
갈색거저리(Tenebrio molitor)는 딱정벌레목(Coleoptera) 거저리과(Tenebrionidae)에 속하는 곤충으로, 갈색거저리 유충에는 50~55%의 단백질과 17종의 아미노산이 함유되어 있으며(유 등, 한국식품영양과학회지 42(2);249, 2013) 그 중 단백질 구성의 필수 재료이며, 근육의 손실을 억제하는 leucine, 단백질 합성을 돕는 시스테인(박 등, 2014. 미래의 단백질 육류고기압가수분해), 어린이들의 성장호르몬의 합성과 성인 체내에서 혈액순환 개선에도 관여하는 아르기닌(조 등, 한국식품영양과학회지, 31;935, 2011)이 다량 함유되어 있다. 또한, 갈색거저리 유충에는 다량의 조지방(30~35%)이 함유되어 있고 총 지방산 중 75∼80%의 많은 불포화지방산이 함유되어 있다. 따라서 풍부한 단백질과 불포화 지방산이 함유된 갈색거저리 유충은 식품소재뿐만 아니라 기능성 식품, 의약품으로서의 활용가치도 높다.The brown mealworm (Tenebrio molitor) is an insect belonging to the Coleoptera family Tenebrionidae. Brown mealworm larvae contain 50-55% protein and 17 types of amino acids (Yu et al., Journal of the Korean Society of Food and Nutrition 42 (2);249, 2013) Among them, leucine, which is an essential ingredient in protein composition and suppresses muscle loss, cysteine, which helps protein synthesis (Park et al., 2014. Future protein meat hyperbaric hydrolysis), and growth hormone for children. It contains a large amount of arginine (Cho et al., Journal of Korean Society of Food and Nutrition, 31;935, 2011), which is involved in synthesis and improvement of blood circulation in the adult body. In addition, brown mealworm larvae contain a large amount of crude fat (30-35%) and 75-80% of the total fatty acids are unsaturated fatty acids. Therefore, brown mealworm larvae, which contain abundant proteins and unsaturated fatty acids, have high utility value not only as food ingredients but also as functional foods and medicines.
갈색거저리 유충를 이용한 선행문헌으로 등록특허 제10-2076459호에는 근육량 증강용 조성물, 등록특허 제10-1962008호에 갈색거저리 유충으로부터 분리된 화합물을 함유하는 항혈전용 조성물, 등록특허 제10-1806474호에는 골질환의 개선, 예방 또는 치료용 조성물이 개시되어 갈색거저리 유충을 원료로 하는 다양한 식품 개발 가능성이 제시되었으나, 인지기능 개선용 조성물을 제공하지는 못하고 있다.Prior literature using brown mealworm larvae includes Patent No. 10-2076459 for a composition for enhancing muscle mass, Patent No. 10-1962008 for an anti-thrombotic composition containing a compound isolated from brown mealworm larvae, and Patent No. 10-1806474 for an anti-thrombotic composition containing a compound isolated from brown mealworm larvae. A composition for improving, preventing or treating bone disease has been disclosed, suggesting the possibility of developing various foods using brown mealworm larvae as a raw material, but a composition for improving cognitive function has not been provided.
이에, 본 발명자들은 각종 곤충과 식물이 갖는 다양한 생리활성을 연구하던 중, 갈색거저리 유충의 효소처리물이 인지기능 개선 효능이 뛰어남을 확인하여 본 발명을 완성하게 되었다.Accordingly, while studying the various physiological activities of various insects and plants, the present inventors confirmed that the enzyme-treated product of brown mealworm larvae was excellent in improving cognitive function, and thus completed the present invention.
본 발명의 목적은 갈색거저리 유충 효소처리물을 포함하는 인지기능 개선용 조성물을 제공하는데 있다.The purpose of the present invention is to provide a composition for improving cognitive function containing enzyme-treated brown mealworm larvae.
본 발명의 다른 목적은 갈색거저리 유충 효소처리물을 포함하는 알츠하이머성 질환의 예방 또는 치료용 약학적 조성물을 제공하는데 있다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating Alzheimer's disease, comprising an enzyme-treated brown mealworm larvae.
본 발명의 또 다른 목적은 갈색거저리 유충 효소처리물을 포함하는 알츠하이머성 질환의 예방 또는 개선용 식품 조성물을 제공하는데 있다.Another object of the present invention is to provide a food composition for preventing or improving Alzheimer's disease containing an enzyme-treated brown mealworm larvae.
본 발명의 또 다른 목적은 갈색거저리 유충 효소처리물을 포함하는 알츠하이머성 질환의 예방 또는 개선용 건강기능식품 조성물을 제공하는데 있다.Another object of the present invention is to provide a health functional food composition for preventing or improving Alzheimer's disease, comprising an enzyme-treated brown mealworm larvae.
본 발명이 해결하고자 하는 과제는 이상에서 언급한 과제(들)로 제한되지 않으며, 언급되지 않은 또 다른 과제(들)는 이하의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The problem to be solved by the present invention is not limited to the problem(s) mentioned above, and other problem(s) not mentioned will be clearly understood by those skilled in the art from the following description.
본 발명은 상기와 같은 목적을 달성하기 위하여, 갈색거저리 유충 효소처리물을 유효성분으로 포함하는 인지기능 개선용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for improving cognitive function containing enzyme-treated brown mealworm larvae as an active ingredient.
상기 갈색거저리 유충 효소처리물은 갈색거저리 유충을 단백질 분해효소로 처리하는 단계를 포함하여 제조되는 것으로, 상기 단백질 분해효소는 플라보자임(Flavourzyme), 알칼라아제(Alcalase), 프로타멕스(Protamax), 뉴트라아제(Neutrase), 파파인(Papain), 브로멜라인(bromelain) 중 하나 또는 둘 이상의 조합에서 선택된 것 일 수 있다.The brown mealworm larva enzyme treatment product is manufactured including the step of treating brown mealworm larvae with a proteolytic enzyme. The proteolytic enzymes include Flavozyme, Alcalase, and Protamax. ), Neutrase, papain, bromelain, or a combination of two or more.
상기 갈색거저리 유충 효소처리물은 갈색거저리 유충을 단백질 분해효소로 처리한 후 당화 효소로 처리하는 단계를 포함하여 제조되는 것으로, 상기 당화 효소는 α-아밀라아제, β-아밀라아제, 디아스타아제, 글루코아밀라아제, 말타아제, 수크라아제중 하나 또는 둘 이상의 조합에서 선택된 것 일 수 있다.The enzyme-treated product of brown mealworm larvae is prepared by treating brown mealworm larvae with a proteolytic enzyme and then treating them with a saccharification enzyme. The saccharification enzymes include α-amylase, β-amylase, diastase, glucoamylase, and maltase. , Sucrase may be selected from one or a combination of two or more.
상기 갈색거저리 유충 효소처리물은 갈색거저리 유충을 탈지하는 단계를 포함하여 제조되는 것 일 수 있다.The brown mealworm larva enzyme treatment product may be prepared including the step of degreasing the brown mealworm larvae.
상기 갈색거저리 유충 효소처리물은 갈색거저리 유충을 분쇄, 탈지, 증숙 및 효소 가수분해 단계를 포함하여 제조되는 것 일 수 있다.The brown mealworm larva enzyme treatment product may be prepared by grinding, defatting, steaming, and enzymatic hydrolysis of brown mealworm larvae.
상기 갈색거저리 유충 효소처리물은 세포독성이 없는 것 일 수 있다.The enzyme-treated brown mealworm larvae may be non-cytotoxic.
상기 갈색거저리 유충 효소처리물은 신경세포 독성으로 인한 신경세포 사멸을 억제하는 것 일 수 있다.The enzyme-treated brown mealworm larvae may inhibit neuronal cell death caused by neuronal cell toxicity.
상기 신경세포 독성은 아밀로이드 베타인 것 일 수 있다.The neuronal cytotoxicity may be amyloid beta.
또한, 본 발명은 상기와 같은 목적을 달성하기 위하여, 갈색거저리 유충 효소처리물을 유효성분으로 포함하는 알츠하이머성 질환의 예방 또는 치료용 약학적 조성물을 제공한다.In addition, in order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of Alzheimer's disease containing enzyme-treated brown mealworm larvae as an active ingredient.
또한, 본 발명은 상기와 같은 목적을 달성하기 위하여, 갈색거저리 유충 효소처리물을 유효성분으로 포함하는 알츠하이머성 질환의 예방 또는 개선용 식품 조성물을 제공한다.In addition, in order to achieve the above object, the present invention provides a food composition for preventing or improving Alzheimer's disease containing enzyme-treated brown mealworm larvae as an active ingredient.
또한, 본 발명은 상기와 같은 목적을 달성하기 위하여, 갈색거저리 유충 효소처리물을 유효성분으로 포함하는 알츠하이머성 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, in order to achieve the above object, the present invention provides a health functional food composition for preventing or improving Alzheimer's disease containing enzyme-treated brown mealworm larvae as an active ingredient.
본 발명에 따른 갈색거저리 유충 효소처리물을 유효성분으로 포함하는 인지기능 개선용 약학적 조성물, 식품 조성물 및 건강기능식품 조성물은 세포 독성이 없고, 아밀로이드 베타로 인하여 독성이 유발된 신경세포를 보호하는 효과가 있다.The pharmaceutical composition, food composition, and health functional food composition for improving cognitive function containing enzyme-treated brown mealworm larvae according to the present invention as an active ingredient is non-cytotoxic and protects nerve cells caused by toxicity due to amyloid beta. It works.
도 1은 본 발명의 일 따른 갈색거저리 유충 효소처리물의 제조방법을 나타낸 것이다.
도 2는 본 발명의 일 실시예에 따른 8종(1~8번)의 갈색거저리 유충 효소처리물을 신경세포에 처리하여 자체 세포독성 평가(CCK-8 assay)한 결과를 나타낸 그래프이다.
도 3a는 은 본 발명의 일 실시예에 따른 1~4번의 갈색거저리 유충 효소처리물을 신경세포에 처리하여 인지기능 개선 효능을 확인한 것이고, 도 3b는 본 발명의 일 실시예에 따른 5~8번의 갈색거저리 유충 효소처리물을 신경세포에 처리하여 인지기능 개선 효능을 확인한 것이다.Figure 1 shows a method for producing an enzyme-treated brown mealworm larva according to the present invention.
Figure 2 is a graph showing the results of self-cytotoxicity evaluation (CCK-8 assay) by treating nerve cells with enzyme-treated products of eight types (Nos. 1 to 8) of brown mealworm larvae according to an embodiment of the present invention.
Figure 3a shows the efficacy of cognitive function improvement by treating nerve cells with enzyme-treated brown mealworm larvae Nos. 1 to 4 according to an embodiment of the present invention, and Fig. 3b shows the efficacy of enzyme treatment for brown mealworm larvae Nos. 1 to 4 according to an embodiment of the present invention. The effect of improving cognitive function was confirmed by treating nerve cells with enzyme-treated brown mealworm larvae.
하기의 설명에서는 본 발명의 실시예를 이해하는데 필요한 부분만이 설명되며, 그 이외 부분의 설명은 본 발명의 요지를 흩트리지 않는 범위에서 생략될 것이라는 것을 유의하여야 한다.It should be noted that in the following description, only the parts necessary to understand the embodiments of the present invention will be described, and descriptions of other parts will be omitted to the extent that they do not distract from the gist of the present invention.
이하에서 설명되는 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념으로 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.Terms or words used in the specification and claims described below should not be construed as limited to their usual or dictionary meanings, and the inventor should use the concept of terminology appropriately to explain his/her invention in the best way. It must be interpreted as meaning and concept consistent with the technical idea of the present invention based on the principle that it can be defined clearly.
따라서, 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 바람직한 실시예에 불과할 뿐이고, 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.Accordingly, the embodiments described in this specification and the configurations shown in the drawings are only preferred embodiments of the present invention and do not represent the entire technical idea of the present invention, and therefore, various equivalents that can replace them at the time of filing the present application may be used. It should be understood that variations and variations may exist.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에서, "인지기능" 이라 함은 기억력, 주의력, 언어 능력, 시공간 능력, 판단력 등을 포함한 뇌의 기능을 의미하는 것이다.In the present invention, “cognitive function” refers to brain functions including memory, attention, language ability, visuospatial ability, judgment, etc.
본 발명에서, "인지기능 개선" 이라 함은 기억력, 주의력, 언어 능력, 시공간 능력, 판단력 등이 저하된 인지기능 장애를 개선하는 것으로, 인지기능 장애의 정도는 경미한 상태에서 심한 경우까지 모두 포함되며, 알츠하이머성 질환도 인지기능 장애에 포함된다.In the present invention, “cognitive function improvement” refers to improving cognitive dysfunction in which memory, attention, language ability, visuospatial ability, judgment, etc. are reduced, and the degree of cognitive dysfunction includes all cases from mild to severe. , Alzheimer's disease is also included in cognitive dysfunction.
본 발명에서, "알츠하이머성 질환" 이라 함은 아밀로이드 베타 단백질의 과도한 생성 및 뇌 침착에 의해 발생하는 뇌 기능 저하, 장애 또는 뇌 질병을 의미한다.In the present invention, "Alzheimer's disease" refers to a decline in brain function, disorder, or brain disease caused by excessive production and brain deposition of amyloid beta protein.
본 발명에서, "약학적 조성물" 이라 함은 사람을 포함한 동물의 질병의 진단, 치료, 경감, 처치 또는 예방을 목적으로 사용하는 약제를 의미한다.In the present invention, “pharmaceutical composition” means a drug used for the purpose of diagnosis, treatment, alleviation, treatment or prevention of diseases in animals, including humans.
본 발명에서,"식품 조성물"이라 함은농ㆍ축ㆍ임ㆍ수산물을 그대로 유통하는 신선식품과, 이들의 원료를 제조 또는 가공 처리하여 저장성, 영양성 등을 높인 가공식품 등을 포함한다.In the present invention, the term "food composition" includes fresh food distributed as is from agricultural, livestock, forestry, and marine products, and processed food whose shelf life and nutritional value have been improved by manufacturing or processing their raw materials.
본 발명에서, "건강기능식품 조성물"이라 함은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 또는 가공한 식품을 의미하고, 기능성 식품(functional food), 영양 보조제(nutritional supplement), 건강식품(health food), 식품 첨가제(food additives) 등의 모든 형태를 포함한다.In the present invention, “health functional food composition” means food manufactured or processed using raw materials or ingredients with functional properties useful to the human body, and includes functional food, nutritional supplement, and health food. Includes all forms of health food, food additives, etc.
본 발명은 갈색거저리 유충 효소처리물을 유효성분으로 포함하는 인지기능 개선용 조성물을 제공한다.The present invention provides a composition for improving cognitive function containing enzyme-treated brown mealworm larvae as an active ingredient.
본 발명의 "갈색거저리(Tenebrio molitor)"는 딱정벌레목(Coleoptera) 거저리과(Tenebrionidae)에 속하는 곤충으로, 갈색거저리의 유충은 밀웜(mealworm)이라고도 불리며 반려동물 또는 작은 동물의 먹이로 이용되고 있고 식품의약품안전처는 갈색거저리 유충을 2016년 일반 식품 원료로 허용하였다.The "brown mealworm (Tenebrio molitor)" of the present invention is an insect belonging to the Coleoptera family Tenebrionidae. The larvae of the brown mealworm are also called mealworms and are used as food for companion animals or small animals and are used as food and drug products. The Ministry of Safety and Security permitted brown mealworm larvae as a general food ingredient in 2016.
본 발명에서 갈색거저리 유충 효소처리물의 원료가 되는 갈색거저리 유충은 5 내지 10령의 유충을 사용할 수 있다.In the present invention, brown mealworm larvae, which are the raw material for the enzyme-treated brown mealworm larvae, can be larvae of 5 to 10 instars.
본 발명에 따른 갈색거저리 유충 효소처리물은 원료의 건조, 탈지, 분쇄, 가압증숙, 효소 가수분해, 효소실활, 여과, 멸균, 농축, 건조의 일부 또는 전부의 과정을 포함하여 제조될 수 있다. 이하 상세히 설명한다.The enzyme-treated product of brown mealworm larvae according to the present invention can be manufactured including some or all of the processes of drying, degreasing, grinding, pressure steaming, enzyme hydrolysis, enzyme deactivation, filtration, sterilization, concentration, and drying of raw materials. This is explained in detail below.
갈색거저리 유충 원료의 건조는 송풍건조, 열풍건조, 동결건조 또는 마이크로웨이브 건조 방법을 이용할 수 있다. 갈색거저리 유충의 건조 시 수분함량은 5% 이하로 조절하는 것이 바람직하다. 이를 위하여, 마이크로웨이브 건조 시 건조실 내부온도는 120℃ 내지 140℃를 유지하고, 건조시간은 5분 내지 10분, 바람직하게는 5분으로 수행할 수 있다. 조사 시간이 5분 보다 적으면 건조된 갈색거저리 유충의 수분함량이 5%를 초과하고 맛과 향미 등 관능이 낮아지는 문제가 발생하며, 10분을 초과하게 되면 벤조피렌이 발생할 수 있다. 열풍건조 온도는 60℃ 내지 80℃, 바람직하게는 60℃ 건조할 수 있다. 건조 온도가 60℃ 보다 낮을 경우 수분함량이 5%를 초과할 수 있으며 80℃ 보다 높을 경우에는 벤조피렌 발생할 수 있다. 이 때 건조 시간은 6시간 내지 10시간, 바람직하게는 8시간으로 수행할 수 있다. 건조시간이 6시간 보다 적을 경우 건조가 잘 되지 않아 수분함량이 5%를 초과할 수 있으며 10시간 보다 높을 경우 벤조피렌이 발생할 수 있다. 동결건조는 -70℃ 내지 -80℃ 에서 24시간 내지 72시간, 바람직하게는 72시간 수행할 수 있다.Drying of brown mealworm larva raw materials can be done using blow drying, hot air drying, freeze drying, or microwave drying methods. When drying brown mealworm larvae, it is desirable to control the moisture content to 5% or less. For this purpose, during microwave drying, the temperature inside the drying room is maintained at 120°C to 140°C, and the drying time is 5 to 10 minutes, preferably 5 minutes. If the irradiation time is less than 5 minutes, the moisture content of dried brown mealworm larvae exceeds 5%, causing problems with lowered sensory properties such as taste and flavor, and if it exceeds 10 minutes, benzopyrene may be generated. The hot air drying temperature may be 60°C to 80°C, preferably 60°C. If the drying temperature is lower than 60℃, the moisture content may exceed 5%, and if the drying temperature is higher than 80℃, benzopyrene may be generated. At this time, the drying time can be 6 to 10 hours, preferably 8 hours. If the drying time is less than 6 hours, drying may not occur properly and the moisture content may exceed 5%, and if the drying time is longer than 10 hours, benzopyrene may be generated. Freeze-drying can be performed at -70°C to -80°C for 24 to 72 hours, preferably 72 hours.
상기 건조된 원료는 롤밀, 핀밀, 커터밀 등의 분쇄기를 이용하여 40mesh 내지 100mesh, 바람직하게는 60mesh 입도의 분말로 제조한다. 분쇄 과정을 거치지 않을 경우 탈지 수율이 낮아지고 효소반응면적이 적어져 가수분해 효율이 낮아지는 문제가 발생할 수 있다.The dried raw material is manufactured into powder with a particle size of 40 mesh to 100 mesh, preferably 60 mesh, using a grinder such as a roll mill, pin mill, or cutter mill. If the grinding process is not performed, the degreasing yield may be lowered and the enzyme reaction area may be reduced, resulting in lower hydrolysis efficiency.
상기 분쇄된 원료의 탈지는 고압착유기를 이용할 수 있다. 고압착유기를 이용할 경우 500kgf/cm2내지 700kgf/cm2,바람직하게는 600kgf/cm2압력에서 45℃ 내지 80℃, 50℃의 온도로 5분 내지 60분, 바람직하게는 40분 동안 수행할 수 있다.Degreasing of the pulverized raw material can be done using a high-pressure oil press. When using a high-pressure milking machine, it can be performed at a pressure of 500kgf/cm 2 to 700kgf/cm 2 , preferably 600kgf/cm 2 , at a temperature of 45°C to 80°C and 50°C for 5 to 60 minutes, preferably 40 minutes. there is.
상기 탈지된 원료의 증숙은 고압멸균기, 고압추출기 등의 장치를 이용할 수 있다. 고압추출기를 이용하여 증숙할 경우 탈지한 건조 갈색거저리 유충을 고압추출기에 넣고 90℃ 내지 120℃, 바람직하게는 100℃의 온도에서 30분 내지 120분, 바람직하게는 60분 동안 고압증기로 증숙 처리를 한다. 증숙 처리를 하지 않을 경우 고소애 건조분말의 함수율 및 팽화율이 낮아져 충분한 효소의 작용이 이루어지지 않을 수 있다.For steaming of the degreased raw materials, devices such as a high-pressure sterilizer and a high-pressure extractor can be used. When steaming using a high-pressure extractor, place defatted dried brown mealworm larvae in the high-pressure extractor and steam them with high-pressure steam at a temperature of 90°C to 120°C, preferably 100°C, for 30 to 120 minutes, preferably 60 minutes. Do. If steaming treatment is not performed, the moisture content and swelling rate of the high-altitude dry powder may be lowered, resulting in insufficient enzyme action.
상기 증숙된 원료의 가수분해에 사용되는 효소제는 식용 단백질 분해효소제로서 플라보자임(Flavourzyme), 알칼라아제(Alcalase), 프로타멕스(Protamax), 뉴트라아제(Neutrase), 파파인(Papain) 및 브로멜라인(bromelain) 중 하나 또는 둘 이상의 조합에서 선택되는 하나일 수 있으며 바람직하게는 알칼라아제를 처리할 수 있다. 효소처리 활성을 높이기 위해 식용 당화 효소제(탄수화물 분해 효소)를 순차적으로 처리할 수 있으며, α-아밀라아제, β-아밀라아제, 디아스타아제, 글루코아밀라아제, 말타아제, 수크라아제 중 하나 또는 둘 이상의 조합에서 선택되는 하나 일 수 있으며, 바람직하게는 알파-아밀라제(α-Amylase)를 사용할 수 있다. 효소 가수분해는 증숙한 갈색거저리 유충 분말 100 중량부 기준 400 내지 1,000 중량부의 정제수, 바람직하게는 1,000 중량부의 정제수를 첨가하고, 80℃ 내지 130℃, 바람직하게는 95℃의 온도에서 30분 내지 2시간, 바람직하게는 30분 동안 가열하며 살균 처리하고, 탱크를 다시 냉각시킨 후 증숙한 갈색거저리 유충 분말 100 중량부 기준 효소(단백질 가수분해 효소, 당화 효소)를 0.1 내지 10 중량부, 바람직하게는 1 중량부를 첨가하여 30℃ 내지 80℃, 바람직하게는 50℃ 내지 80℃의 온도와 pH5 내지 pH8 에서 4시간 내지 12시간, 바람직하게는 4시간 내지 8시간 동안 가수분해를 수행할 수 있다.The enzymes used for hydrolysis of the steamed raw materials are edible proteolytic enzymes such as Flavozyme, Alcalase, Protamax, Neutrase, Papain, and bromide. It may be one selected from bromelain or a combination of two or more, and is preferably treated with alcalase. To increase enzyme processing activity, edible saccharification enzymes (carbohydrate decomposition enzymes) can be processed sequentially, one selected from α-amylase, β-amylase, diastase, glucoamylase, maltase, and sucrase, or a combination of two or more. It may be, preferably alpha-amylase (α-Amylase) may be used. Enzymatic hydrolysis is performed by adding 400 to 1,000 parts by weight of purified water, preferably 1,000 parts by weight, based on 100 parts by weight of steamed brown mealworm larva powder, and heating at a temperature of 80 ℃ to 130 ℃, preferably 95 ℃ for 30 minutes to 2. 0.1 to 10 parts by weight of enzyme (protein hydrolytic enzyme, saccharifying enzyme) based on 100 parts by weight of steamed brown mealworm larva powder is sterilized by heating for an amount of time, preferably 30 minutes, and the tank is cooled again, preferably 0.1 to 10 parts by weight. By adding 1 part by weight, hydrolysis can be performed at a temperature of 30°C to 80°C, preferably 50°C to 80°C and pH 5 to pH8 for 4 to 12 hours, preferably 4 to 8 hours.
가수분해를 마친 후 효소의 실활을 위해서 90℃ 내지 100℃, 바람직하게는 95℃에서 20분 내지 60분, 바람직하게는 30분간 가열하여 효소를 실활시킨 후 냉각할 수 있다.After completion of hydrolysis, the enzyme can be deactivated by heating at 90°C to 100°C, preferably 95°C, for 20 to 60 minutes, preferably 30 minutes, and then cooled.
효소 실활을 마친 가수분해물 중의 침전물을 제거하기 위하여 여과하는 과정으로 멸균필터, 연속식 원심분리기 등을 이용할 수 있다. 가수분해물의 여과 과정은 연속식 원심분리기를 이용하여 12,000rpm 내지 16,000rpm, 바람직하게는 16,000rpm의 속도로 원심분리한 후 60mesh 내지 300mesh, 바람직하게는 120mesh 멸균필터를 통과시켜 침전물은 제거하고 상층액을 회수할 수 있다.A sterilizing filter, continuous centrifuge, etc. can be used as a filtration process to remove sediment from the hydrolyzate after enzyme deactivation. The filtration process of the hydrolyzate is centrifuged at a speed of 12,000 rpm to 16,000 rpm, preferably 16,000 rpm, using a continuous centrifuge, and then passed through a 60 mesh to 300 mesh, preferably 120 mesh sterilizing filter to remove sediment and supernatant. can be recovered.
농축 과정은 여과된 상층액을 농축탱크로 이송한 후 60℃ 내지 100℃, 바람직하게는 60℃에서 30brix 내지 50brix 바람직하게는 40brix로 농축할 수 있다.In the concentration process, the filtered supernatant is transferred to a concentration tank and then concentrated to 30 brix to 50 brix, preferably 40 brix, at 60°C to 100°C, preferably 60°C.
가수분해물의 건조는 열풍건조기, 동결건조기, 스프레이드라이(Spray dry) 및 감압건조기(Vaccume dry)를 이용할 수 있으며, 바람직하게는 원료의 안정성을 높일 수 있는 동결건조기가 적당하다. 동결건조 조건은 관채 온도 -50℃ 내지 -80℃, 바람직하게는 -80℃, 트레이 온도 -40℃ 내지 -60℃, 바람직하게는 -50℃의 온도에서 24시간 내지 72시간, 바람직하게는 72시간 건조할 수 있다.For drying the hydrolyzate, a hot air dryer, freeze dryer, spray dryer, and vacuum dryer can be used. Preferably, a freeze dryer is suitable as it can increase the stability of the raw materials. Freeze-drying conditions are 24 to 72 hours, preferably 72 hours, at a tube temperature of -50°C to -80°C, preferably -80°C, and a tray temperature of -40°C to -60°C, preferably -50°C. It can take some time to dry.
상기와 같이 제조된 갈색거저리 유충 효소처리물은 탈지되고 효소 가수분해되어, 극성의 저분자 펩타이드 화합물을 주요 성분으로 포함할 수 있다.The enzyme-treated brown mealworm larvae prepared as described above is defatted and enzymatically hydrolyzed, and may contain a polar low-molecular-weight peptide compound as a main ingredient.
본 발명의 실시예에서는 갈색거저리를 다양한 효소의 조합으로 처리하여 제조한 갈색거저리 유충 효소처리물 8종을 신경세포에 처리한 결과, 갈색거저리 유충 효소처리물은 세포독성이 없고, 아밀로이드 베타로 독성 유발된 신경세포를 보호하는 효능이 있음을 확인하였다.In an example of the present invention, eight types of brown mealworm larva enzyme-treated products prepared by treating brown mealworms with a combination of various enzymes were treated with nerve cells. As a result, the brown mealworm larva enzyme-treated products were not cytotoxic and were not toxic due to amyloid beta. It was confirmed that it has the effect of protecting induced nerve cells.
본 발명의 갈색거저리 유충 효소처리물은 세포독성이 없는 것을 특징으로 한다. 본 발명의 실시예 1을 참조하면, 8종의 갈색거저리 유충 효소처리물은 신경세포에 처리시 세포독성을 나타내지 않았다(도 2).The enzyme-treated brown mealworm larvae of the present invention is characterized by no cytotoxicity. Referring to Example 1 of the present invention, the enzyme-treated products of eight types of brown mealworm larvae did not show cytotoxicity when treated with nerve cells (FIG. 2).
본 발명의 갈색거저리 유충 효소처리물은 신경세포 독성으로 독성 유발된 신경세포를 보호하는 것을 특징으로 한다. 상기 신경세포 독성은 아밀로이드 베타 일 수 있다. 본 발명의 실시예 2를 참조하면, 신경세포에 아밀로이드 베타와 8종의 갈색거저리 유충 효소처리물을 함께 처리시 신경세포 사멸을 억제하는 효능이 있음을 확인하였다(도 3a, 도 3b).The enzyme-treated product of brown mealworm larvae of the present invention is characterized by protecting nerve cells caused by toxicity due to nerve cell toxicity. The neuronal cytotoxic agent may be amyloid beta. Referring to Example 2 of the present invention, it was confirmed that treating nerve cells with amyloid beta and 8 types of enzyme-treated brown mealworm larvae had an effect in suppressing nerve cell death (FIGS. 3A, 3B).
본 발명은 전술한 갈색거저리 유충 효소처리물을 유효성분으로 포함하는 알츠하이머성 질환의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating Alzheimer's disease, comprising the above-described enzyme-treated brown mealworm larvae as an active ingredient.
본 발명의 상기 약학적 조성물에 포함되는 갈색거저리 유충 효소처리물의 제조방법, 함량 및 효능은 상기 인지기능 개선용 조성물에 설명한 것과 중복되므로 기재를 생략한다.The manufacturing method, content, and efficacy of the enzyme-treated brown mealworm larva included in the pharmaceutical composition of the present invention overlap with those described in the composition for improving cognitive function, and thus description is omitted.
본 발명의 상기 약학적 조성물에 포함되는 갈색거저리 유충 효소처리물은 농축물 형태로 냉동 보관하거나, 건조 또는 동결건조시킨 후 분말화한 것을 사용하는 것이 바람직하지만, 이에 한정되는 것은 아니다.The enzyme-treated brown mealworm larva contained in the pharmaceutical composition of the present invention is preferably stored frozen in the form of a concentrate or dried or freeze-dried and then powdered, but is not limited thereto.
본 발명의 상기 약학적 조성물의 투여 용량은 환자의 나이, 몸무게, 성별, 투여형태, 건강상태 및 질환의 정도에 따라 달라질 수 있으며, 의사 또는 약사의 판단에 따라 일정 시간 간격으로 1일 1회 내지 수회로 분할 투여할 수도 있다.The administered dose of the pharmaceutical composition of the present invention may vary depending on the patient's age, weight, gender, dosage form, health condition, and degree of disease, and may be administered from once a day at regular time intervals according to the judgment of a doctor or pharmacist. It may be administered in several divided doses.
본 발명의 상기 약학적 조성물은 의학적으로 허용 가능한 임의의 투여 방식을 사용하여 실시될 수 있다. 이러한 투여 방식으로는 경구, 직장, 국소, 비강, 피내 또는 비경구 경로가 있다. 용어 "비경구"는 피하, 정맥내, 근육내 또는 주입을 포함한다. 정맥내 또는 근육내 경로는 장기간의 요법 및 예방법에는 특히 적합하지 않다. 그러나 이들은 응급 상황에서는 바람직할 수 있다. 경구 투여가 개체의 편리 및 투여 일정을 위하여 바람직하다.The pharmaceutical composition of the present invention can be administered using any medically acceptable administration method. These modes of administration include oral, rectal, topical, nasal, intradermal, or parenteral routes. The term “parenteral” includes subcutaneous, intravenous, intramuscular or infusion. Intravenous or intramuscular routes are not particularly suitable for long-term therapy and prophylaxis. However, they may be desirable in emergency situations. Oral administration is preferred for individual convenience and administration schedule.
본 발명의 상기 약학적 조성물은 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention can be prepared using pharmaceutically suitable and physiologically acceptable auxiliaries, and the auxiliaries include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, lubricants, or Flavoring agents, etc. can be used.
본 발명의 상기 약학적 조성물은 투여를 위해서 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다. 약제 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제 및 유제 등이 될 수 있으나, 이에 한정되지는 않는다.The pharmaceutical composition of the present invention may be preferably formulated as a pharmaceutical composition by further including one or more pharmaceutically acceptable carriers for administration. Pharmaceutical preparation forms may include, but are not limited to, granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, and emulsions.
예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다.For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, etc. Additionally, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture.
적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다.Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, Includes sodium acetate, sodium chloride, etc.
상기 붕해제는 이에 제한되는 것은 아니지만, 녹말, 메틸 셀룰로스, 아가로스, 벤토나이트, 잔탄 검 등을 포함한다.The disintegrant includes, but is not limited to, starch, methyl cellulose, agarose, bentonite, xanthan gum, etc.
액상 용액으로 제제화되는 약학적 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 환약, 캡슐, 과립 또는 정제 등으로 제제화할 수 있다.Acceptable pharmaceutical carriers in pharmaceutical compositions formulated as liquid solutions include those that are sterile and biocompatible, such as saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, Ethanol and one or more of these ingredients can be mixed and used, and other common additives such as antioxidants, buffers, and bacteriostatic agents can be added as needed. Additionally, diluents, dispersants, surfactants, binders, and lubricants can be additionally added to formulate pills, capsules, granules, or tablets such as aqueous solutions, suspensions, and emulsions.
비경구 투여를 위한 제제로는 멸균 수성 또는 비수성 용액, 현탁액 및 유화액이 있다. 비수성 용매의 예는 프로필렌 글리콜, 폴리에틸렌 글리콜, 식물성 오일(예: 올리브유) 및 주사가능한 유기 에스테르(예: 에틸 올리에이트)이다.Formulations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils (e.g. olive oil) and injectable organic esters (e.g. ethyl oleate).
수성 담체로는 식염수 및 완충 매질을 포함하여 물, 알콜/수용액, 유화액 또는 현탁액이 있다. 비경구 부형제로는 염화나트륨 용액, 링거(Ringer) 덱스트로즈, 덱스트로즈 및 염화 나트륨, 락테이트화 링거 또는 고정 오일이 있다. 정맥내 부형제로는 유체 및 영양 보충액, 전해질 보충액(예: 링거 덱스트로즈를 기본으로 하는 것) 등이 있다. 방부제 및 다른 첨가제, 예를 들어 항균제, 산화방지제, 킬레이트제 및 불활성 기체 등도 또한 존재할 수도 있다.Aqueous carriers include water, alcohol/aqueous solutions, emulsions or suspensions, including saline solutions and buffered media. Parenteral excipients include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishment solutions and electrolyte replenishment solutions (e.g., those based on Ringer's dextrose). Preservatives and other additives such as antibacterial agents, antioxidants, chelating agents and inert gases may also be present.
본 발명은 전술한 갈색거저리 유충 효소처리물을 유효성분으로 포함하는 알츠하이머성 질환의 예방 또는 개선용 식품 조성물을 제공한다.The present invention provides a food composition for preventing or improving Alzheimer's disease, comprising the above-described enzyme-treated brown mealworm larvae as an active ingredient.
본 발명의 상기 식품 조성물에 포함되는 갈색거저리 유충 효소처리물의 제조방법, 함량 및 효능은 상기 인지기능 개선용 조성물에 설명한 것과 중복되므로 기재를 생략한다.Since the manufacturing method, content, and efficacy of the enzyme-treated brown mealworm larva included in the food composition of the present invention overlap with those described in the composition for improving cognitive function, description is omitted.
본 발명의 상기 식품 조성물에 포함되는 갈색거저리 유충 효소처리물은 농축물 형태로 냉동 보관하거나, 건조 또는 동결건조시킨 후 분말화한 것을 사용하는 것이 바람직하지만, 이에 한정되는 것은 아니다.The enzyme-treated brown mealworm larva included in the food composition of the present invention is preferably stored frozen in the form of a concentrate or dried or freeze-dried and then powdered, but is not limited thereto.
본 발명의 상기 식품 조성물은 식품학적으로 허용되는 첨가제, 부형제, 향미제 등을 추가로 포함할 수 있으나, 이에 한정되는 것은 아니다.The food composition of the present invention may further include foodologically acceptable additives, excipients, flavoring agents, etc., but is not limited thereto.
본 발명의 상기 식품 조성물에서, 상기 식품으로는 정제, 캡슐제, 과립, 분말, 티백, 파우치, 환제, 조미료, 곡물제품, 스프, 소스, 오일, 액상 제제, 음료수, 껌, 아이스크림, 초콜렛, 차, 드링크제, 알코올 음료, 유제품, 우유, 치즈, 육류제품, 유동식, 죽, 빵, 케이크, 캔디, 스낵류, 과자류, 영양바, 면류 또는 비타민 복합제 등을 예로 들 수 있으나, 이에 한정되는 것은 아니다.In the food composition of the present invention, the food includes tablets, capsules, granules, powders, tea bags, pouches, pills, seasonings, grain products, soups, sauces, oils, liquid preparations, beverages, gum, ice cream, chocolate, and tea. , drinks, alcoholic beverages, dairy products, milk, cheese, meat products, liquid foods, porridge, bread, cakes, candies, snacks, confectionery, nutritional bars, noodles, or vitamin complexes, but are not limited to these.
본 발명은 전술한 갈색거저리 유충 효소처리물을 유효성분으로 포함하는알츠하이머성 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention provides a health functional food composition for preventing or improving Alzheimer's disease, comprising the above-described enzyme-treated brown mealworm larvae as an active ingredient.
본 발명의 상기 건강기능식품 조성물에포함되는 갈색거저리 유충 효소처리물의 제조방법, 함량 및 효능은 상기 인지기능 개선용 조성물에 설명한 것과 중복되므로 기재를 생략한다.The manufacturing method, content, and efficacy of the enzyme-treated brown mealworm larva contained in the health functional food composition of the present invention overlap with those described in the composition for improving cognitive function, and thus description is omitted.
본 발명의 상기 건강기능식품 조성물에 포함되는 갈색거저리 유충 효소처리물은 농축물 형태로 냉동 보관하거나, 건조 또는 동결건조시킨 후 분말화한 것을 사용하는 것이 바람직하지만, 이에 한정되는 것은 아니다.The enzyme-treated brown mealworm larva included in the health functional food composition of the present invention is preferably stored frozen in the form of a concentrate or dried or freeze-dried and then powdered, but is not limited thereto.
본 발명의 상기 건강기능식품 조성물은당업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다. 예를 들면, 건강기능식품으로는 본 발명의 갈색거저리 유충 효소처리물을 차, 쥬스 및 드링크의 형태로 제조하여 음용하도록 하거나, 과립화, 캡슐화 및 분말화하여 섭취할 수 있다.The health functional food composition of the present invention can be prepared in various forms according to conventional methods known in the art. For example, as a health functional food, the enzyme-treated product of brown mealworm larvae of the present invention can be prepared and consumed in the form of tea, juice, and drinks, or granulated, encapsulated, and powdered.
또한, 기능성 식품으로는 예컨대, 음료(알콜성 음료 포함), 과실 및 그의 가공식품(예: 과일통조림, 병조림, 잼, 마말레이드 등), 어류, 육류 및 그 가공식품(예: 햄,소시지 콘비프등), 빵류 및 면류(예: 우동, 메밀국수, 라면, 스파게티, 마카로니 등), 과즙, 각종 드링크, 쿠키, 엿, 유제품(예: 버터, 치즈 등), 식용식물유지, 마가린, 식물성 단백질, 레토르트 식품, 냉동식품, 각종 조미료(예: 된장, 간장, 소스 등) 등에 본 발명의 갈색거저리 유충 효소처리물을첨가하여 제조할 수 있으나, 이에 한정되는 것은 아니다.In addition, functional foods include, for example, beverages (including alcoholic beverages), fruits and processed foods (e.g., canned fruit, bottled foods, jam, marmalades, etc.), fish, meat and their processed foods (e.g., ham, sausage, corned beef, etc.) ), bread and noodles (e.g. udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, taffy, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine, vegetable protein, retort It can be manufactured by adding the enzyme treatment of brown mealworm larvae of the present invention to food, frozen food, various seasonings (e.g., soybean paste, soy sauce, sauce, etc.), but is not limited thereto.
이하, 구체적인 실시예를 통하여 본 발명을 더욱 상세하게 설명하기로 한다. 본 발명의 범위는 하기 제시된 실시예 이외에도 다양한 변형이 가능하며, 실시예에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be described in more detail through specific examples. The scope of the present invention is capable of various modifications in addition to the examples presented below, and is not limited by the examples.
재료 및 방법Materials and Methods
마우스 해마 유래 HT-22 세포주는 AmericanType Culture Collection(ATCC, Rockville, MD, USA)에서 구입하였으며 10% FBS(GIBCO, CA, USA)와 1% Antibiotic-Antimycotic(GIBCO, CA, USA)을 함유한 DMEM(Corning, NY, USA) 배지를 사용하여 배양하였다.The mouse hippocampus-derived HT-22 cell line was purchased from AmericanType Culture Collection (ATCC, Rockville, MD, USA) and cultured in DMEM containing 10% FBS (GIBCO, CA, USA) and 1% Antibiotic-Antimycotic (GIBCO, CA, USA). (Corning, NY, USA) was cultured using medium.
신경세포 사멸 물질의 적정 농도 설정 (CCK-8 assay): HT-22 세포는 10% FBS가 포함된 DMEM 배지에 5 × 103cells/well로 분주한 뒤 24시간 동안 배양하여 glutamate를 농도별로 처리한 후 24시간 동안 배양하였다. 각 well에 CCK-8(Dojindo Laboratories, Kumamoto, Japan) 용액을 가한 후 microplate reader로 450 nm에서 흡광도를 측정하였으며, glutamate로 인하여 유의적으로 세포사멸이 일어난 농도를 사용하였다.Setting the appropriate concentration of neuronal cell death substances (CCK-8 assay): HT-22 cells were distributed at 5 × 10 3 cells/well in DMEM medium containing 10% FBS, cultured for 24 hours, and treated with glutamate at different concentrations. Afterwards, it was cultured for 24 hours. After adding CCK-8 (Dojindo Laboratories, Kumamoto, Japan) solution to each well, absorbance was measured at 450 nm with a microplate reader, and the concentration that significantly caused cell death due to glutamate was used.
아밀로이드 베타(Amyloid beta, Aβ; Abcam, Cambridge, MA, USA)는 올리고머를 형성하여 사용하였다. Aβ를 1,1,1,3,3,3-hexafluoro-2-propanol(HFIP; Sigama, St. Louis, MO, USA)에 녹인 후 휘발시키고, 1mg/ml 농도가 되게 HFIP로 다시 녹인 후 5분 동안 초음파 추출을 진행하였다. 100μL씩 소분하여 HFIP를 휘발시킨 후 ?80℃에서 보관하고, DMSO와 DPBS로 용해시킨 후 세포에 처리하기 전 4℃에서 24시간 이상 배양한 후 사용하였다.Amyloid beta (Aβ; Abcam, Cambridge, MA, USA) was used to form oligomers. Aβ was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigama, St. Louis, MO, USA), volatilized, and dissolved again in HFIP to a concentration of 1 mg/ml for 5 days. Ultrasonic extraction was performed for 10 minutes. HFIP was volatilized in aliquots of 100 μL each, stored at -80°C, dissolved in DMSO and DPBS, and incubated at 4°C for more than 24 hours before being used.
시료의 세포 실험 적정 농도 설정 (CCK-8 assay): HT-22 세포는 10% FBS가 포함된 DMEM 배지에 3 × 103cells/well로 분주한 뒤 24시간 동안 배양하여 Aβ를 농도별로 처리한 후 24시간 동안 배양하였다. 각 well에 CCK-8(Dojindo Laboratories, Kumamoto, Japan) 용액을 가한 후 microplate reader로 450 nm에서 흡광도를 측정하였으며, Aβ로 인하여 유의적으로 세포사멸이 일어난 농도를 사용하였다.Setting the appropriate cell concentration of the sample (CCK-8 assay): HT-22 cells were distributed at 3 × 10 3 cells/well in DMEM medium containing 10% FBS and cultured for 24 hours to treat Aβ at each concentration. Afterwards, it was cultured for 24 hours. After adding CCK-8 (Dojindo Laboratories, Kumamoto, Japan) solution to each well, the absorbance was measured at 450 nm with a microplate reader, and the concentration that caused significant cell death due to Aβ was used.
시료의 신경세포사멸 억제 여부 평가 (CCK-8 assay): HT-22 세포를 96 well plate에 5 × 103cells/well로 분주한 뒤 24시간 동안 배양하고 하기 제조예에서 준비된 갈색거저리 샘플 8종을 농도별로 처리한 후 24시간 동안 배양하였다. 각 well에 CCK-8(Dojindo Laboratories, Kumamoto, Japan) 용액을 가한 후 microplate reader로 450 nm에서 흡광도를 측정하였다.Evaluation of whether the sample inhibits neuronal apoptosis (CCK-8 assay): HT-22 cells were dispensed at 5 were treated at different concentrations and cultured for 24 hours. CCK-8 (Dojindo Laboratories, Kumamoto, Japan) solution was added to each well, and the absorbance was measured at 450 nm using a microplate reader.
통계 분석은 GraphPad Prism®9.1 (Graphpad Software Inc, CA, USA) 프로그램을 이용하여 평균±표준오차(mean±SEM)로 표기하였다. 각 실험군 간의 유의성 검증을 위하여 일원 배치 분산 분석(one-way ANOVA)으로 분석하였으며 post-hoc Tukey's test 로 분석하여, 유의수준 p-value＜0.05 인 경우 유의성이 있는 것으로 평가하였다.Statistical analysis was expressed as mean±standard error (mean±SEM) using the GraphPad Prism®9.1 (Graphpad Software Inc, CA, USA) program. To verify the significance between each experimental group, it was analyzed by one-way ANOVA and post-hoc Tukey's test, and significance was evaluated when the significance level of p-value < 0.05 was found.
제조예: 갈색거저리 유충 효소처리물 8종의 제조Production example: Production of 8 types of enzyme-treated brown mealworm larvae
이하 실시예에서 사용된 갈색거저리 유충 효소처리물은 다음의 1) 내지 8)의 단계로 제조되었다.The enzyme-treated brown mealworm larva used in the examples below was prepared in the following steps 1) to 8).
1) 세척 및 탈수 단계: 8령의 갈색거저리 유충을 2~3일간 절식시킨 다음 이물질을 제거하고, 정제수로 3회 세척하되, 매회 10분 동안 교반하여 세척한 다음, 실온(25℃)에서 5시간 동안 방치하여 탈수하였다.1) Washing and dehydration step: 8-instar brown mealworm larvae are fasted for 2-3 days, then foreign substances are removed, washed 3 times with purified water, washed with agitation for 10 minutes each time, and then washed at room temperature (25°C) for 5 days. It was left to stand for some time and dehydrated.
2) 가열 전처리 및 건조 단계: 세척, 탈수된 갈색거저리 유충에 18kw의 출력을 갖는 마이크로웨이브 건조기를 이용하여 마이크로파를 6분간 조사하여 가열 전처리하였다. 이 때 마이크로파를 통해 유충 내부의 온도가 130℃가 유지되게 하였다. 가열 전처리를 마친 후에는 갈색거저리 유충을 40℃의 온도로 냉각하였고, 그 다음으로 70℃의 온도에서 8시간 동안 열풍건조하였다.2) Heating pretreatment and drying step: Washed and dehydrated brown mealworm larvae were subjected to heating pretreatment by irradiating microwaves for 6 minutes using a microwave dryer with an output of 18kw. At this time, the temperature inside the larva was maintained at 130°C using microwaves. After completing the heating pretreatment, the brown mealworm larvae were cooled to a temperature of 40°C and then dried with hot air at a temperature of 70°C for 8 hours.
3) 분쇄 단계: 30마력 삼상모터가 장착된 HACCP 기준에 맞춘 미세분쇄기(KSJ-400, Korea Patent R&D Institution, Korea)에 건조된 갈색거저리 유충을 투입하여 분말 입도가 80~100mesh 가 되도록 분쇄하였다.3) Grinding step: Dried brown mealworm larvae were put into a fine grinder (KSJ-400, Korea Patent R&D Institution, Korea) compliant with HACCP standards equipped with a 30-horsepower three-phase motor and ground to a powder particle size of 80 to 100 mesh.
4) 탈지 단계: 3마력 삼상모터가 장착된 반자동 유압 착유기(DB-600, Dongbang Machine, Korea)에 열풍건조 및 분쇄를 마친 갈색거저리 유충 분말 3kg을 투입하여 80℃에서 30분 동안 600kgf/cm2압력으로 착유하였다.4) Degreasing step: Inject 3 kg of hot air-dried and pulverized brown mealworm larva powder into a semi-automatic hydraulic milking machine (DB-600, Dongbang Machine, Korea) equipped with a 3-horsepower three-phase motor and heat at 600 kgf/cm 2 for 30 minutes at 80°C. Milked under pressure.
5) 증숙 단계: 탈지된 갈색거저리 유충 분말을 증숙기에 넣은 다음 1~1.5 kgf/cm2및 온도 90~110℃의 가압고온 조건에서 60~90분간 가열하여 살균 및 연화시켰다.5) Steaming step: Degreased brown mealworm larva powder was placed in a steamer and then heated for 60 to 90 minutes under pressurized high temperature conditions of 1 to 1.5 kgf/cm 2 and a temperature of 90 to 110°C to sterilize and soften it.
6) 효소처리 단계: 상기 유충 분말 100 중량부 기준으로 정제수를 900 중량부 혼합하고 효소를 아래 표 1 및 표 2의 투입량과 조건으로 처리하였다. 표 2의 시험군 1번의 효소 비처리군은 효소처리물의 제조방법 중 6) 단계의 효소처리 과정을 제외하고 동일한 방법으로 제조되었다.6) Enzyme treatment step: 900 parts by weight of purified water was mixed with 100 parts by weight of the larvae powder, and the enzyme was treated with the dosage and conditions shown in Tables 1 and 2 below. The enzyme-free group of Test Group No. 1 in Table 2 was manufactured in the same manner except for the enzyme treatment process in step 6) of the enzyme-treated product manufacturing method.
7) 여과처리 단계: 상기 효소처리물을 산업용 원심분리기(Tubular Type, Hanil Science Medical, Korea)를 이용하여 14,000~16,000 rpm 고속조건에서 유속 300 rpm 조건으로 여과한다.7) Filtration treatment step: The enzyme-treated product is filtered using an industrial centrifuge (Tubular Type, Hanil Science Medical, Korea) at a high speed of 14,000 to 16,000 rpm and a flow rate of 300 rpm.
8) 농축 및 건조 단계: 상기 여과액을 90~100℃의 조건에서 60분간 가열하여 살균처리한 다음 55~65℃가 되도록 온도를 내려 35~40 Brix가 되도록 농축하였고, 이렇게 제조한 후 동결건조하여 얻은 분말을 갈색거저리 유충의 효소처리물이라 하였다.8) Concentration and drying step: The filtrate was sterilized by heating at 90-100℃ for 60 minutes, then lowered to 55-65℃ and concentrated to 35-40 Brix, and then freeze-dried. The powder obtained was called the enzyme-treated product of brown mealworm larvae.
모든 값은 삼중 측정의 평균 ± SD로 표시됨. 같은 열 내에서 다른 문자(a-g)를 가진 평균은 Duncan의 다중 범위 검정에 의해 p<0.05에서 유의하게 다름.All values are expressed as mean ± SD of triplicate measurements. Means with different letters (a-g) within the same column are significantly different at p<0.05 by Duncan's multiple range test.
표 3을 참조하면, 가수분해 효소별 추출 수율은 아밀라아제를 처리하지 않고 프로테아제만 단독 처리했을 경우 수율이 더 높은 것을 확인하였다. 표 4를 참조하면, 이화학적 특성 분석 결과 효소처리군에서 당도와 점도가 증가하였으나 효소별로 유의적인 차이는 보이지 않았다.Referring to Table 3, it was confirmed that the extraction yield for each hydrolytic enzyme was higher when only protease was treated without amylase treatment. Referring to Table 4, as a result of physicochemical property analysis, sugar content and viscosity increased in the enzyme-treated group, but no significant difference was seen by enzyme.
이하 실시예에서는, 상기 제조된 8종의 시료를 인산염 완충 식염수(PBS)에 녹이고 0.22 μm 필터하여 200 mg/mL stock을 만든 후 배양배지에 혼합하여 각 시료별로 0.25mg/mL, 0.5mg/mL, 1mg/mL로 제조하고 상기 [재료 및 방법]에 기재된 대로 신경세포(HT-22 세포)에 처리하여 실험을 수행하였다.In the following examples, the eight samples prepared above were dissolved in phosphate-buffered saline (PBS), filtered 0.22 μm to create a 200 mg/mL stock, and mixed with culture medium to produce 0.25 mg/mL and 0.5 mg/mL for each sample. , was prepared at 1 mg/mL and the experiment was performed by treating nerve cells (HT-22 cells) as described in [Materials and Methods] above.
실시예 1: 세포독성 평가 (CCK-8 assay)Example 1: Cytotoxicity evaluation (CCK-8 assay)
상기 제조예에서 준비된 갈색거저리 유충 효소처리물 8종 시료의 자체 세포독성 평가(CCK-8 assay)를 수행하였고, 그 결과를 도 2로 나타내었다.Self-cytotoxicity evaluation (CCK-8 assay) was performed on eight samples of enzyme-treated brown mealworm larvae prepared in the above production example, and the results are shown in Figure 2.
도 2를 참조하면, 실험한 모든 농도에서 세포독성이 나타나지 않았다.Referring to Figure 2, no cytotoxicity was observed at all concentrations tested.
실시예 2: 인지기능개선 평가Example 2: Evaluation of cognitive function improvement
HT-22 세포에 올리고머 형태의 아밀로이드 베타(Aβ)로 세포사멸을 유도하여 상기 제조예에서 준비된 갈색거저리 유충 효소처리물 8종의 효능을 확인하는 실험을 수행하였다. 아밀로이드 베타와 상기 8종의 시료를 함께 처리하여 아밀로이드 베타에 의한 세포 사멸 억제 효능(CCK-8 assay)을 확인하고, 그 결과를 도 3a 및 도 3b로 나타내었다(# p<0.05 vs VC, *p<0.05, **p<0.01, ***p<0.001 vs con).An experiment was conducted to confirm the efficacy of the eight types of enzyme-treated brown mealworm larvae prepared in the above preparation example by inducing apoptosis in HT-22 cells with oligomeric amyloid beta (Aβ). Amyloid beta and the above eight samples were treated together to confirm the cell death inhibition effect caused by amyloid beta (CCK-8 assay), and the results are shown in Figures 3a and 3b (# p < 0.05 vs VC, * p<0.05, **p<0.01, ***p<0.001 vs con).
도 3a 및 도 3b를 참조하면, 갈색거저리 유충 효소처리물 8종 시료는 아밀로이드 베타에 의한 신경세포 독성으로부터 신경세포를 보호하는 효과를 나타내었다. 특히, 효소 비처리군인 1번 조성물은 저농도에서 신경세포 보호 효능이 낮은데 반하여 효소 처리군인 2~8번 조성물은 대체적으로 저농도에서도 높은 신경세포 보호 효능을 나타내었고, 특히 3번, 4번, 6번, 7번 조성물은 테스트한 모든 농도, 즉 저농도에서 고농도까지 모두 유의적인 보호 효과가 나타났다. 올리고머 형태의 아밀로이드 베타는 알츠하이머 질환의 가장 잘 알려진 원인 물질로서, 갈색거저리 유충 효소처리물은 아밀로이드 베타로 인한 세포 사멸을 억제하여 신경세포를 보호하므로 알츠하이머성 질환의 치료 또는 예방에 효능이 있음이 확인되었다.Referring to Figures 3a and 3b, eight samples of enzyme-treated brown mealworm larvae showed an effect in protecting nerve cells from nerve cell toxicity caused by amyloid beta. In particular, composition No. 1, which was the non-enzyme treatment group, had low neuronal cell protection efficacy at low concentrations, whereas compositions No. 2 to 8, which were the enzyme treated group, generally showed high neuronal cell protection efficacy even at low concentrations, especially Nos. 3, 4, and 6. , Composition No. 7 showed a significant protective effect at all concentrations tested, that is, from low to high concentrations. Amyloid beta in the form of an oligomer is the most well-known causative agent of Alzheimer's disease. Enzyme treatment of brown mealworm larvae protects nerve cells by inhibiting cell death caused by amyloid beta, and has been confirmed to be effective in the treatment or prevention of Alzheimer's disease. It has been done.
실시예 3: 갈색거저리 유충 효소처리물 8종의 성분 분석Example 3: Analysis of 8 types of enzyme-treated brown mealworm larvae ingredients
1) 유리아미노산 (18종), GABA, BAIBA, 타우린, 히드록시프롤린을 분석하였고, 그 결과를 하기 표 5(단위: mg/g)로 나타내었다.1) Free amino acids (18 types), GABA, BAIBA, taurine, and hydroxyproline were analyzed, and the results are shown in Table 5 below (unit: mg/g).
[분석 계산식][Analysis calculation formula]
2) 구성아미노산 (18종), 히드록시프롤린을 분석하였고, 그 결과는 하기 표 6(단위: mg/g)으로 나타내었다.2) Constituent amino acids (18 types) and hydroxyproline were analyzed, and the results are shown in Table 6 below (unit: mg/g).
[분석 계산식][Analysis calculation formula]
3) 표준화 할 수 있는 기능/지표물질을 확보하고자 갈색거저리 유충 효소처리물 8종에 대하여 아미노산 2~10개로 구성된 다빈도 펩타이드를 확인하고, 펩타이드 서열을 확인하였다. 이를 표 3으로 기재하였다.3) In order to secure functional/indicator substances that can be standardized, high-frequency peptides consisting of 2 to 10 amino acids were identified for 8 types of enzyme-treated brown mealworm larvae, and the peptide sequences were confirmed. This is listed in Table 3.
표 7에 따르면, 본 발명에 따른 갈색거저리 유충 효소처리물에는 기능/지표물질로 저분자 펩타이드가 함유되어 있음을 알 수 있다. 또한 추가 분석결과 3, 4, 7번의 펩타이드의 함량이 높았다.According to Table 7, it can be seen that the enzyme-treated product of brown mealworm larvae according to the present invention contains low-molecular-weight peptides as functional/indicator substances. Additionally, additional analysis showed that the content of peptides 3, 4, and 7 was high.
지금까지 본 발명의 일 실시예에 따른 갈색거저리 유충 효소처리물을 포함하는 인지기능 개선용 조성물, 알츠하이머성 질환의 예방 또는 치료용 약학적 조성물, 알츠하이머성 질환의 예방 또는 개선용 식품 조성물, 및 알츠하이머성 질환의 예방 또는 개선용 건강기능식품 조성물에 관한 구체적인 실시예에 관하여 설명하였으나, 본 발명의 범위에서 벗어나지 않는 한도 내에서는 여러 가지 실시 변형이 가능함은 자명하다.So far, a composition for improving cognitive function containing an enzyme-treated product of brown mealworm larvae according to an embodiment of the present invention, a pharmaceutical composition for preventing or treating Alzheimer's disease, a food composition for preventing or improving Alzheimer's disease, and an Alzheimer's disease Although specific examples of the health functional food composition for preventing or improving sexual diseases have been described, it is obvious that various modifications can be made without departing from the scope of the present invention.
그러므로. 본 발명의 범위는 설명된 실시예에 국한되어 정해져서는 안 되며, 후술하는 청구범위뿐만 아니라 이 청구범위와 균등한 것들에 의해 정해져야 한다.therefore. The scope of the present invention should not be limited to the described embodiments, but should be determined by the claims described below as well as equivalents to these claims.
즉, 전술된 실시예는 모든 면에서 예시적인 것이며, 한정적인 것이 아닌 것으로 이해되어야 하며, 본 발명의 범위는 상세한 설명보다는 후술될 청구범위에 의하여 나타내어지며, 그 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.That is, the above-described embodiments should be understood in all respects as illustrative and not restrictive, and the scope of the present invention is indicated by the claims to be described later rather than the detailed description, and the meaning and scope of the claims and their equivalents. All changes or modified forms derived from the concept should be construed as falling within the scope of the present invention.
Claims (11)
인지기능 개선용 조성물.Characterized in that it contains an enzyme-treated product of brown mealworm larvae as an active ingredient,
Composition for improving cognitive function.
상기 갈색거저리 유충 효소처리물은 갈색거저리 유충을 단백질 분해효소로 처리하는 단계를 포함하여 제조되는 것으로,
상기 단백질 분해효소는 플라보자임(Flavourzyme), 알칼라아제(Alcalase), 프로타멕스(Protamax), 뉴트라아제(Neutrase), 파파인(Papain), 브로멜라인(bromelain) 중 하나 또는 둘 이상의 조합에서 선택된 것을 특징으로 하는,
인지기능 개선용 조성물.According to paragraph 1,
The brown mealworm larva enzyme-treated product is manufactured including the step of treating brown mealworm larvae with a proteolytic enzyme,
The proteolytic enzyme is one or a combination of two or more of Flavozyme, Alcalase, Protamax, Neutrase, Papain, and bromelain. Characterized by being selected,
Composition for improving cognitive function.
상기 갈색거저리 유충 효소처리물은 갈색거저리 유충을 단백질 분해효소로 처리한 후 당화 효소로 처리하는 단계를 포함하여 제조되는 것으로,
상기 당화 효소는 α-아밀라아제, β-아밀라아제, 디아스타아제, 글루코아밀라아제, 말타아제, 수크라아제 중 하나 또는 둘 이상의 조합에서 선택된 것을 특징으로 하는,
인지기능 개선용 조성물.According to paragraph 2,
The brown mealworm larva enzyme treatment product is manufactured by treating brown mealworm larvae with a proteolytic enzyme and then treating them with a saccharification enzyme,
The saccharification enzyme is selected from one or a combination of two or more of α-amylase, β-amylase, diastase, glucoamylase, maltase, and sucrase,
Composition for improving cognitive function.
상기 갈색거저리 유충 효소처리물은
갈색거저리 유충을 탈지하는 단계를 포함하여 제조되는 것을 특징으로 하는,
인지기능 개선용 조성물.According to paragraph 1,
The brown mealworm larvae enzyme treatment product is
Characterized in that it is manufactured including the step of degreasing brown mealworm larvae,
Composition for improving cognitive function.
상기 갈색거저리 유충 효소처리물은
갈색거저리 유충을 분쇄, 탈지, 증숙 및 효소 가수분해 단계를 포함하여 제조되는 것을 특징으로 하는,
인지기능 개선용 조성물.According to paragraph 1,
The brown mealworm larvae enzyme treatment product is
Characterized in that it is manufactured including the steps of grinding, defatting, steaming, and enzymatic hydrolysis of brown mealworm larvae,
Composition for improving cognitive function.
상기 갈색거저리 유충 효소처리물은
세포독성이 없는 것을 특징으로 하는,
인지기능 개선용 조성물.According to paragraph 1,
The brown mealworm larvae enzyme treatment product is
Characterized by no cytotoxicity,
Composition for improving cognitive function.
상기 갈색거저리 유충 효소처리물은
신경세포 독성으로 인한 신경세포 사멸을 억제하는 것을 특징으로 하는,
인지기능 개선용 조성물.According to paragraph 1,
The brown mealworm larvae enzyme treatment product is
Characterized by inhibiting neuronal cell death caused by neuronal cytotoxicity,
Composition for improving cognitive function.
상기 신경세포 독성은 아밀로이드 베타인 것을 특징으로 하는,
인지기능 개선용 조성물.In clause 7,
Characterized in that the neuronal cytotoxicity is amyloid beta,
Composition for improving cognitive function.
알츠하이머성 질환의 예방 또는 치료용 약학적 조성물.Characterized in that it contains an enzyme-treated product of brown mealworm larvae as an active ingredient,
Pharmaceutical composition for preventing or treating Alzheimer's disease.
알츠하이머성 질환의 예방 또는 개선용 식품 조성물.Characterized in that it contains an enzyme-treated product of brown mealworm larvae as an active ingredient,
Food composition for preventing or improving Alzheimer's disease.
알츠하이머성 질환의 예방 또는 개선용 건강기능식품 조성물.Characterized in that it contains an enzyme-treated product of brown mealworm larvae as an active ingredient,
Health functional food composition for preventing or improving Alzheimer's disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220141351A KR20240062225A (en) | 2022-10-28 | 2022-10-28 | Composition for improving cognitive function containing enzyme-treated Tenebrio molitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220141351A KR20240062225A (en) | 2022-10-28 | 2022-10-28 | Composition for improving cognitive function containing enzyme-treated Tenebrio molitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240062225A true KR20240062225A (en) | 2024-05-09 |
Family
ID=91075371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220141351A KR20240062225A (en) | 2022-10-28 | 2022-10-28 | Composition for improving cognitive function containing enzyme-treated Tenebrio molitor |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20240062225A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101806474B1 (en) | 2016-10-25 | 2017-12-07 | 순천향대학교 산학협력단 | A composition for improving, preventing and treating of bone diseases comprising Tenebrio molitor extract |
| KR101962008B1 (en) | 2017-03-24 | 2019-03-25 | 대한민국(농촌진흥청장) | Composition comprising compound isolated from Tenebrio molitor larva for antithrombosis |
| KR102076459B1 (en) | 2019-10-29 | 2020-02-13 | 주식회사 한미양행 | Composition containing enzyme treatmented Tenebrio molitor for muscle mass enhancement and restorative rejuvenation of recovering patients or elderly patients |
-
2022
- 2022-10-28 KR KR1020220141351A patent/KR20240062225A/en not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101806474B1 (en) | 2016-10-25 | 2017-12-07 | 순천향대학교 산학협력단 | A composition for improving, preventing and treating of bone diseases comprising Tenebrio molitor extract |
| KR101962008B1 (en) | 2017-03-24 | 2019-03-25 | 대한민국(농촌진흥청장) | Composition comprising compound isolated from Tenebrio molitor larva for antithrombosis |
| KR102076459B1 (en) | 2019-10-29 | 2020-02-13 | 주식회사 한미양행 | Composition containing enzyme treatmented Tenebrio molitor for muscle mass enhancement and restorative rejuvenation of recovering patients or elderly patients |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101982326B1 (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
| KR100902539B1 (en) | Functional drink comprising abalone extract and the preparation method of thereof | |
| KR20030069991A (en) | Homeostasis-maintaining agents | |
| JP5594819B2 (en) | Composition for improving lipid metabolism | |
| KR102620997B1 (en) | Composition for protecting eyesight or improving and preventing retinal diseases comprising extracts of stewartia pseudocamellia maxim | |
| KR20210014231A (en) | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract | |
| US20040219238A1 (en) | Remedies | |
| KR102086166B1 (en) | Antimicrobial composition comprising the extracts of rambutan peel | |
| KR102243591B1 (en) | Antimicrobial composition comprising the extract of rodgersia podophylla | |
| KR101602552B1 (en) | Antimicrobial composition comprising the extract of cornus officinalis | |
| JPWO2004112817A1 (en) | Celery family-derived extract and method for producing the same | |
| KR102143937B1 (en) | Composition contaning herbal mixture extract for improving, alleviating or treating side-effect of anticancer drug | |
| KR102185919B1 (en) | Composition contaning herbal mixture extract for improving, alleviating or treating side-effect of anticancer drug | |
| KR101976201B1 (en) | Antimicrobial composition comprising the sprout extract of zingiber officinale | |
| JP2012246244A (en) | Capillary regression inhibitor | |
| KR20240062225A (en) | Composition for improving cognitive function containing enzyme-treated Tenebrio molitor | |
| KR20200022926A (en) | Use of Chrysanthemum boreale extract for eye health | |
| KR20200022930A (en) | Use of Arctium lappa extract for eye health | |
| KR102184823B1 (en) | Antioxidant composition containing blackcurrant, lingonberry and sea buckthorn extract | |
| KR20170057213A (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| KR20180075763A (en) | Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage | |
| KR20160056655A (en) | Composition for inhibiting obesity comprising complex salt of baicalin and zinc | |
| KR20240062226A (en) | Composition for inhibiting aging of muscle cells containing enzyme treated Tenebrio molitor | |
| KR20200084560A (en) | Anti-inflammatory composition comprising extract of Scapharca broughtonii hydrolysate as effective component | |
| KR102561733B1 (en) | Composition for ameliorating blood circulation comprising extract of Capsicum annuum by-product as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E601 | Decision to refuse application |